Why the study?
Does ticlopidine or aspirin reduce platelet aggregability measured by the whole blood SFP method in post-thrombotic stroke patients?
Population
110 subjects, including 85 post-thrombotic stroke patients in the chronic phase and 25 normal controls…
Comparison
Ticlopidine 200 mg/day or Aspirin 330 mg/day. vs Normal controls without medication.
Design
Cross-sectional
Authors
Loading...
May support SFP method for monitoring antiplatelet effects in stroke patients; leaves open outcome prediction.
Does ticlopidine or aspirin reduce platelet aggregability measured by the whole blood SFP method in post-thrombotic stroke patients?
The novel whole blood aggregometer using the screen filtration pressure method effectively detects the anti-platelet effects of ticlopidine and aspirin in clinical settings.
Kondoh et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: